

ANSWERING REVIEWERS



September 15, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 5049-review.doc).

Title: Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment

Author: Girolamo Ranieri, Ilaria Marech, Vito Lorusso, Veronica Goffredo, Angelo Paradiso, Domenico Ribatti, Cosmo Damiano Gadaleta

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 5049

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) In detail, in reply to **Reviewer 00070577**:

1. The title of the manuscript has been changed in "Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment" because of the efficacy of some drugs is not only angiogenesis, as you have suggested.
2. With regard to the effects of thalidomide, we have added at page 9, line nine that it is an angiogenesis inhibitor and, thus, the reference [41] has been changed into the following: "D'Amato RJ, Loughnan MS, Flynn E, Folkman. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-4085".
3. We added all missing references in the manuscript (such as at previous page 7, last paragraph: "In fact, TACE was associated with a high rate of disease recurrence, with 67% of post-therapy deaths due to tumor progression[3])"
4. We have rewritten the manuscript to make the focus more clearly and shorten the manuscript for the general readers, as you have suggested.

(2) In detail, in reply to **Reviewer 00182864** we have added pictures showing HCC before and after the procedures (TACE and RFA).

(3) In detail, in reply to **Reviewer 00742216**:

1. We have added at page 3, line one (at previous page 3, last line) the reference regarding the increase in the level of VEGF-A after the TACE treatment.

2. We have added at page 9, line nine (at previous page 7, last line) the reference regarding 67% of death of post-TACE due to tumor progression.
3. In fig. 1 we have included the molecular targeting agents with potential angiogenesis inhibition cited in our paper.
4. The title of the manuscript has been changed in "Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment" because of the efficacy of some drugs is not only angiogenesis, as you have suggested.

(4) In detail, in reply to you:

1. I certify that the attached manuscript has now been edited by a native English speaker in our in-house publications department and has reached Grade A standard.
2. We have reformat all the reference numbers (superscript with square brackets) without blank space between reference number and the before words. We have reformatted the manuscript with normal line space (i.e.1).
3. We have left the figures embodied in the text, moreover we have attached all figures decomposable as power point format, thus you can edit them easily.
4. In tables we have reformatted all the reference numbers (superscript with square brackets) without blank space between reference number and the before words.
5. References and typesetting were corrected, in fact we have added PubMed citation numbers and DOI citation to the reference list and list of all authors.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.



Yours sincerely,

Girolamo Ranieri M.D.,
Interventional Radiology Unit with Integrated Section of Translational Medical Oncology
National Cancer Research Centre Istituto Tumori "Giovanni Paolo II"
Via Orazio Flacco 65
70124 Bari (Italy)
Telephone: 0039 080 5555561
Fax: 0039 080 5555563
e-mail: giroran@tiscalinet.it